Novel Antidiabetic Medications in Polycystic Ovary Syndrome.

Autor:	Somagutta MR; Avalon University School of Medicine, Willemstad, Curacao., Jain M; Saint James School of Medicine, Park Ridge, Illinois, USA., Uday U; West Bengal University of Health Sciences, Kolkata, India., Pendyala SK; Avalon University School of Medicine, Willemstad, Curacao., Mahadevaiah A; Jagadguru Sri Shivarathreeshwara (JSS) University, Mysore, India., Mahmutaj G; The University of Medicine, Tirana, Albania., Jarapala N; Atlantic University School of Medicine, Gross islet, St. Lucia., Gad MA; Saint George's School of Medicine, St. George's, Grenada., Srinivas PM; Avalon University School of Medicine, Willemstad, Curacao., Sasidharan N; Academy of Medical Sciences, Pariyaram, Kerala, India., Mustafa N; The National Ribat University Khartoum, Sudan.
Jazyk:	angličtina
Zdroj:	Discoveries (Craiova, Romania) [Discoveries (Craiova)] 2022 Mar 31; Vol. 10 (1), pp. e145. Date of Electronic Publication: 2022 Mar 31 (Print Publication: 2022).
DOI:	10.15190/d.2022.4
Abstrakt:	Polycystic ovary syndrome is a very common endocrine disorder prevalent in premenopausal women. Patients with polycystic ovary syndrome present with abnormal menstruation, ovulation disorders, and hyperandrogenemia. They are often accompanied by insulin resistance, metabolic disorders, and other cardiovascular abnormalities. Also, they have comorbidities, such as dyslipidemia, obesity, diabetes type 2, non-alcoholic fatty liver disease, which all influence the treatment plan. Metformin has been defined as a treatment option in patients with polycystic ovary syndrome. However, the clinical responses to metformin are limited. Thus, the need for novel treatments with a broad range of coverage for the complications is warranted. Sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, incretin analogs are novel drugs approved for treating type-2 diabetes. Because of their recorded benefit with weight loss, improved insulin resistance, and cardiovascular benefits in recent studies, they may help polycystic ovary syndrome women address the polycystic ovary syndrome-related risk of metabolic, reproductive, and psychological consequences. Limited literature is available on the safety and efficacy of these novel antidiabetic drugs in patients with polycystic ovary syndrome. Thus, this review is investigating the role and effectiveness of novel antidiabetic medication as an early therapeutic option in polycystic ovary syndrome. Competing Interests: Conflict of interests: The authors declare no conflicts of interest. (Copyright © 2022, Somagutta MR et al., Applied Systems and Discoveries Journals.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu